Calcitonin gene-related peptide-targeted therapies for migraine.

IF 3.4 Q2 PHARMACOLOGY & PHARMACY

Australian Prescriber Pub Date : 2025-04-01 DOI:10.18773/austprescr.2025.017

Stephanie Barnes, Lucie Aldous, Bronwyn Jenkins

{"title":"Calcitonin gene-related peptide-targeted therapies for migraine.","authors":"Stephanie Barnes, Lucie Aldous, Bronwyn Jenkins","doi":"10.18773/austprescr.2025.017","DOIUrl":null,"url":null,"abstract":"<p><p>Calcitonin gene-related peptide (CGRP)-targeted therapies are the first medications developed specifically for migraine prevention. They block the actions of CGRP, a neuropeptide with a key role in migraine pathophysiology. There are 2 categories of drugs: monoclonal antibodies directed against either the CGRP ligand or receptor, and small-molecule CGRP receptor antagonists. CGRP monoclonal antibodies are available as self-administered subcutaneous injections or as an intravenous infusion, and are administered monthly or quarterly. Clinical trial and real-world data over the past 10 years support their effectiveness and safety in patients with episodic and chronic migraines, and research into long-term safety is ongoing. Patients must fulfil certain criteria, including prior treatment with nonspecific oral preventive medications, to receive subsidised treatment with these drugs on the Pharmaceutical Benefits Scheme (PBS) in Australia. Small-molecule CGRP receptor antagonists (known as gepants) are orally administered drugs that can be used for migraine prevention or acute treatment. There are no gepants listed on the PBS at the time of writing. Their role in the prevention and acute treatment of migraine is continuing to evolve.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"40-46"},"PeriodicalIF":3.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055492/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18773/austprescr.2025.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Calcitonin gene-related peptide (CGRP)-targeted therapies are the first medications developed specifically for migraine prevention. They block the actions of CGRP, a neuropeptide with a key role in migraine pathophysiology. There are 2 categories of drugs: monoclonal antibodies directed against either the CGRP ligand or receptor, and small-molecule CGRP receptor antagonists. CGRP monoclonal antibodies are available as self-administered subcutaneous injections or as an intravenous infusion, and are administered monthly or quarterly. Clinical trial and real-world data over the past 10 years support their effectiveness and safety in patients with episodic and chronic migraines, and research into long-term safety is ongoing. Patients must fulfil certain criteria, including prior treatment with nonspecific oral preventive medications, to receive subsidised treatment with these drugs on the Pharmaceutical Benefits Scheme (PBS) in Australia. Small-molecule CGRP receptor antagonists (known as gepants) are orally administered drugs that can be used for migraine prevention or acute treatment. There are no gepants listed on the PBS at the time of writing. Their role in the prevention and acute treatment of migraine is continuing to evolve.

查看原文本刊更多论文

降钙素基因相关肽靶向治疗偏头痛。

降钙素基因相关肽（CGRP）靶向治疗是第一个专门用于偏头痛预防的药物。它们阻断CGRP的作用，CGRP是一种在偏头痛病理生理中起关键作用的神经肽。有两类药物：针对CGRP配体或受体的单克隆抗体和小分子CGRP受体拮抗剂。CGRP单克隆抗体可自行皮下注射或静脉输注，每月或每季度给药。过去10年的临床试验和实际数据支持其对发作性和慢性偏头痛患者的有效性和安全性，长期安全性的研究正在进行中。患者必须符合某些标准，包括之前接受过非特异性口服预防药物治疗，才能在澳大利亚的药物福利计划（PBS）中获得这些药物的补贴治疗。小分子CGRP受体拮抗剂（称为gepants）是一种口服药物，可用于偏头痛预防或急性治疗。在撰写本文时，PBS上没有列出任何妊娠。它们在偏头痛的预防和急性治疗中的作用正在不断发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian Prescriber MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY

CiteScore

3.80

自引率

7.40%

发文量

审稿时长

>12 weeks

期刊介绍： Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online. Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information. As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas. We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.